MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 (“ASCO GI”) has been accepted. RenovoRx will present its findings from a pharmacokinetic and phar ...